Published in JAMA on December 12, 2001
Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement. J Clin Endocrinol Metab (2012) 2.78
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2006) 2.24
Consensus report of the National Medical Association. The role of dairy and dairy nutrients in the diet of African Americans. J Natl Med Assoc (2004) 2.05
Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab (2009) 1.93
The incidence and residual lifetime risk of osteoporosis-related fractures in Korea. J Bone Miner Metab (2011) 1.88
Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int (2011) 1.77
FRAX or fiction: determining optimal screening strategies for treatment of osteoporosis in residents in long-term care facilities. J Am Geriatr Soc (2012) 1.64
Risks and benefits of hormone replacement therapy: the evidence speaks. CMAJ (2003) 1.63
Longitudinal trends in use of bone mass measurement among older americans, 1999-2005. J Bone Miner Res (2008) 1.55
Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int (2006) 1.52
The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int (2006) 1.52
The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. Osteoporos Int (2005) 1.51
Meta-analysis of genome-wide scans for total body BMD in children and adults reveals allelic heterogeneity and age-specific effects at the WNT16 locus. PLoS Genet (2012) 1.49
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Use of pragmatic community-based interventions to enhance recruitment and adherence in a randomized trial of Tai Chi for women with osteopenia: insights from a qualitative substudy. Menopause (2014) 1.46
Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int (2008) 1.46
Ethnicity-related skeletal muscle differences across the lifespan. Am J Hum Biol (2009) 1.42
Individual trabecula segmentation (ITS)-based morphological analyses and microfinite element analysis of HR-pQCT images discriminate postmenopausal fragility fractures independent of DXA measurements. J Bone Miner Res (2012) 1.40
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study. Breast Cancer Res (2005) 1.39
Aging bone in men and women: beyond changes in bone mineral density. Osteoporos Int (2003) 1.39
Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial. Osteoporos Int (2009) 1.20
Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women. J Midlife Health (2011) 1.20
FRAX assessment of osteoporotic fracture probability in Switzerland. Osteoporos Int (2009) 1.19
Association between change in BMD and fragility fracture in women and men. J Bone Miner Res (2009) 1.19
Disparities in osteoporosis screening between at-risk African-American and white women. J Gen Intern Med (2005) 1.16
Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int (2005) 1.16
Longitudinal changes in BMD and bone geometry in a population-based study. J Bone Miner Res (2008) 1.15
Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2008) 1.15
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int (2011) 1.14
Mineral metabolism markers and the long-term risk of hip fracture: the cardiovascular health study. J Clin Endocrinol Metab (2011) 1.12
Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. Osteoporos Int (2009) 1.12
BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int (2009) 1.12
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Identifying older Chinese immigrants at high risk for osteoporosis. J Gen Intern Med (2003) 1.09
Fracture Reduction Affects Medicare Economics (FRAME): impact of increased osteoporosis diagnosis and treatment. Osteoporos Int (2005) 1.07
Identify fracture-critical regions inside the proximal femur using statistical parametric mapping. Bone (2008) 1.07
Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int (2007) 1.07
Bone density in relation to alcohol intake among men and women in the United States. Osteoporos Int (2006) 1.06
Calcium and vitamin D intake influence bone mass, but not short-term fracture risk, in Caucasian postmenopausal women from the National Osteoporosis Risk Assessment (NORA) study. Osteoporos Int (2007) 1.06
Performance of osteoporosis risk assessment tools in postmenopausal women aged 45-64 years. Osteoporos Int (2004) 1.05
Bone health in healthy Indian population aged 50 years and above. Osteoporos Int (2011) 1.05
Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2007) 1.05
Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc (2004) 1.05
Prevalence of osteoporosis using bone mineral measurements at the calcaneus by dual X-ray and laser (DXL). Osteoporos Int (2003) 1.02
Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab (2008) 1.02
Ethnic differences in composite indices of femoral neck strength. Osteoporos Int (2011) 1.01
Relationship between bone mineral density, leptin and insulin concentration in Brazilian obese adolescents. J Bone Miner Metab (2009) 1.01
Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment. Osteoporos Int (2011) 1.00
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. Osteoporos Int (2007) 1.00
Screening and early diagnosis of osteoporosis through X-ray and ultrasound based techniques. World J Radiol (2013) 0.99
Management of cancer treatment-induced bone loss. Nat Rev Rheumatol (2013) 0.99
Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporos Int (2010) 0.99
Risk factors for hip fracture in women with high BMD: EPIDOS study. Osteoporos Int (2004) 0.98
Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab (2009) 0.98
Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). Osteoporos Int (2005) 0.97
Dental panoramic radiograph as a tool to detect postmenopausal women with low bone mineral density: untrained general dental practitioners' diagnostic performance. Osteoporos Int (2003) 0.97
An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture. Osteoporos Int (2007) 0.96
Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis. Mol Biol Rep (2012) 0.96
Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone (2011) 0.96
Hydrogel microsphere encapsulation of a cell-based gene therapy system increases cell survival of injected cells, transgene expression, and bone volume in a model of heterotopic ossification. Tissue Eng Part A (2010) 0.96
Clinical risk factors for osteoporotic fractures in Brazilian women and men: the Brazilian Osteoporosis Study (BRAZOS). Osteoporos Int (2008) 0.95
Do patients receive recommended treatment of osteoporosis following hip fracture in primary care? BMC Fam Pract (2006) 0.95
Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int (2005) 0.95
Low body mass index can identify majority of osteoporotic inflammatory bowel disease patients missed by current guidelines. ScientificWorldJournal (2012) 0.95
Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int (2007) 0.94
Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int (2012) 0.94
Different effects of age, adiposity and physical activity on the risk of ankle, wrist and hip fractures in postmenopausal women. Bone (2012) 0.94
Racial/ethnic differences in bone mineral density among older women. J Bone Miner Metab (2012) 0.93
Bone mineral density enhances use of clinical risk factors in predicting ten-year risk of osteoporotic fractures in Chinese men: the Hong Kong Osteoporosis Study. Osteoporos Int (2011) 0.93
Abnormalities in cortical bone, trabecular plates, and stiffness in postmenopausal women treated with glucocorticoids. J Clin Endocrinol Metab (2014) 0.93
Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women. Osteoporos Int (2013) 0.93
Fracture risk assessment without race/ethnicity information. J Clin Endocrinol Metab (2012) 0.93
Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do? Patient Prefer Adherence (2012) 0.93
Low Bone Mineral Density in Middle-Aged Breast Cancer Survivors: Prevalence and Associated Factors. Breast Care (Basel) (2012) 0.93
Bone health in urban midlife Malaysian women: risk factors and prevention. Osteoporos Int (2005) 0.93
Factors associated with diagnosis and treatment of osteoporosis in older adults. Osteoporos Int (2009) 0.92
Differential effect of obesity on bone mineral density in White, Hispanic and African American women: a cross sectional study. Nutr Metab (Lond) (2005) 0.92
Evaluation of easily measured risk factors in the prediction of osteoporotic fractures. BMC Musculoskelet Disord (2005) 0.91
Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int (2007) 0.91
Is bone quality associated with collagen age? Osteoporos Int (2009) 0.91
Timing and risk factors for clinical fractures among postmenopausal women: a 5-year prospective study. BMC Med (2006) 0.91
Evaluation of FRAX to characterise fracture risk in Poland. Osteoporos Int (2010) 0.90
Bone mineral density measurement in the calcaneus with DXL: comparison with hip and spine measurements in a cross-sectional study of an elderly female population. Osteoporos Int (2004) 0.90
Spine radiographs to improve the identification of women at high risk for fractures. Osteoporos Int (2008) 0.90
A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol (2015) 0.90
Relationship between vitamin D and inflammatory markers in older individuals. Age (Dordr) (2014) 0.90
Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland. Osteoporos Int (2012) 0.90
The prevalence and risk factors of vertebral fractures in Korea. J Bone Miner Metab (2011) 0.89
What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos Int (2010) 0.89
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial. BMC Musculoskelet Disord (2010) 0.89
Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2006) 0.88
Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: particle size effect. J Med Food (2012) 0.88
Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. Osteoporos Int (2006) 0.88
Influence of fracture history and bone mineral density testing on the treatment of osteoporosis in two non-academic community centers. Osteoporos Int (2004) 0.88
Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. BMC Womens Health (2012) 0.88
Economic comparison of diagnostic approaches for evaluating osteoporosis in older women. Osteoporos Int (2005) 0.87
Factors influencing the treatment of osteoporosis following fragility fracture. Osteoporos Int (2009) 0.87
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res (2000) 7.29
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Central obesity and increased risk of dementia more than three decades later. Neurology (2008) 6.03
The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis (1971) 4.88
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Differences between respondents and non-respondents in a population-based cardiovascular disease study. Am J Epidemiol (1978) 3.90
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
A classification of marginal tissue recession. Int J Periodontics Restorative Dent (1985) 3.62
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 3.49
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology (2004) 3.47
Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) (1971) 3.40
Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res (1994) 3.29
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Burden of migraine in the United States: disability and economic costs. Arch Intern Med (1999) 3.05
The prevalence of peripheral arterial disease in a defined population. Circulation (1985) 2.88
Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc (2000) 2.80
Latent and chronic infections imported from Southeast Asia. JAMA (1978) 2.78
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet (1985) 2.62
The epidemiology of head injury: a prospective study of an entire community-San Diego County, California, 1978. Am J Epidemiol (1981) 2.58
Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA (1983) 2.57
Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol (1994) 2.50
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
From outcomes research to disease management: a guide for the perplexed. Ann Intern Med (1996) 2.38
Regulation of parathyroid hormone secretion: proportional control by calcium, lack of effect of phosphate. Endocrinology (1968) 2.36
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation (1999) 2.31
Exercise patterns in a population of older adults. Am J Prev Med (1989) 2.28
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int (2006) 2.24
Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer (2011) 2.20
A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med (1986) 2.18
Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation (1997) 2.17
Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study. Am J Epidemiol (1982) 2.15
Cognitive and functional status of the oldest old. J Am Geriatr Soc (1996) 2.14
Effects of passive smoking on ischemic heart disease mortality of nonsmokers. A prospective study. Am J Epidemiol (1985) 2.12
Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation (2001) 2.12
Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol (1997) 2.06
A prospective population-based study of alcohol use and non-insulin-dependent diabetes mellitus. Am J Epidemiol (1990) 2.05
Dietary calcium and risk of hip fracture: 14-year prospective population study. Lancet (1988) 2.05
Eosinophilic prostatitis and prostatic specific antigen. Br J Urol (1992) 2.04
The effect of parity on the later development of non-insulin-dependent diabetes mellitus or impaired glucose tolerance. N Engl J Med (1989) 2.03
Indirect cost of ischemic heart disease to employers. Am J Manag Care (2001) 2.03
Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res (1997) 2.03
Production of parathyroid hormone by nonparthyroid tumors. J Clin Endocrinol Metab (1967) 2.00
Payment for labour in monkeys. Nature (2000) 2.00
A prospective study of alcohol consumption and bone mineral density. BMJ (1993) 1.99
Depressive symptoms in overweight and obese older adults: a test of the "jolly fat" hypothesis. J Psychosom Res (1996) 1.97
Quality assurance for bone densitometry research studies: concept and impact. Osteoporos Int (1993) 1.96
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med (1998) 1.96
Noncontraceptive estrogen use and cardiovascular disease. Epidemiol Rev (1985) 1.95
Dietary potassium and stroke-associated mortality. A 12-year prospective population study. N Engl J Med (1987) 1.95
GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo Study. Diabetes Care (1996) 1.90
Physical exercise, sports, and lung function in smoking versus nonsmoking adolescents. Eur Respir J (2002) 1.89
Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Study of Osteoporotic Fractures Research Group. Osteoporos Int (1994) 1.88
Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab (2000) 1.88
Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med (1988) 1.88
Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med (2001) 1.87
Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A (1985) 1.86
Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol (1998) 1.86
Health problems in teenage daily smokers versus nonsmokers, Norway, 1995-1997: the Nord-Trøndelag Health Study. Am J Epidemiol (2000) 1.85
Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int (1993) 1.84
Transplantation of the parathyroid glands in man: clinical indications and results. Surgery (1975) 1.84
Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol (1993) 1.81
Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med (1999) 1.81
Evidence for a precursor to circulating parathyroid hormone. Proc Natl Acad Sci U S A (1970) 1.81
The postwar hospitalization experience of U.S. veterans of the Persian Gulf War. N Engl J Med (1996) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Parathyroid hormone: chemical properties and structural requirements for biological and immunological activity. Recent Prog Horm Res (1966) 1.74
The effect of response bias on the odds ratio. Am J Epidemiol (1981) 1.73
Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation (1984) 1.73
Evaluation by radioimmunoassay of factors controlling the secretion of parathyroid hormone. Nature (1966) 1.71
Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol (1998) 1.70
Ischemic heart disease risk factors after age 50. J Chronic Dis (1984) 1.69
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Sex differential in ischemic heart disease mortality in diabetics: a prospective population-based study. Am J Epidemiol (1983) 1.66
The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab (2015) 1.61
Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int (2007) 1.61
Diabetes and pancreatic carcinoma. Diabete Metab (1994) 1.59
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
A prospective study of Type 2 diabetes and depressive symptoms in the elderly: the Rancho Bernardo Study. Diabet Med (2004) 1.58
Estrogen replacement therapy and the risk of venous thrombosis. Am J Med (1992) 1.58
Management of prolonged pregnancy: induction of labor versus antepartum fetal testing. Am J Obstet Gynecol (1987) 1.56
Chemoprophylaxis of malaria for travelers. Ann Intern Med (1974) 1.55
The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation (1985) 1.52
Pregnancy and lactation as determinants of bone mineral density in postmenopausal women. Am J Epidemiol (1992) 1.52
Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab (2000) 1.51
Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med (2001) 1.51
Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med (2013) 1.51
A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int (1998) 1.50
Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA (1996) 1.48
The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol (1983) 1.46
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med (1996) 1.46
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int (2011) 1.45
Alcohol consumption and blood pressure. The lipid research clinics prevalence study. Hypertension (1982) 1.44